{
    "nctId": "NCT00070252",
    "briefTitle": "Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer",
    "officialTitle": "Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 With Docetaxel and Capecitabine for Patients With Stage IIIA or IIIB Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Adult Solid Neoplasm, Inflammatory Breast Carcinoma, Male Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 53,
    "primaryOutcomeMeasure": "Dose-limiting toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (Phase I)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed solid tumor\n\n  * Locally advanced or metastatic\n* No known standard therapy that is potentially curative or definitely capable of extending life expectancy\n* No history of metastatic brain disease within the past 6 months\n\n  * Treated metastatic brain disease is allowed provided disease has been stable for more than 6 months and does not require concurrent steroids or anti-seizure medication\n* Histologically confirmed breast cancer\n\n  * Stage IIIA or stage IIIB, including ipsilateral palpable supraclavicular lymph node(s) without other distant metastasis\n  * Invasive disease confirmed by 1 of the following\\*:\n\n    * Incisional biopsy\n    * Punch biopsy (applicable for clinical T4b tumors)\n    * Core needle (cutting needle) biopsies\n* No distant metastatic disease\n* Hormone receptor status:\n\n  * Not specified\n* Male or female\n* Performance status - ECOG 0-1\n* Absolute neutrophil count at least 2,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Hemoglobin at least 10.0 g/dL\n* Bilirubin no greater than upper limit of normal (ULN)\n* Alkaline phosphatase no greater than 2.5 times ULN\n* AST no greater than 2.5 times ULN\n* Creatinine no greater than 1.25 times ULN\n* Creatinine clearance at least 50 mL/min\n* No cardiac arrhythmia\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No active infection requiring antibiotics\n* No diabetes\n* No symptomatic neurologic condition\n* No other uncontrolled serious medical condition\n* No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No history of hypersensitivity to intravenous paclitaxel or other medication containing Cremophor EL or polysorbate 80 as a carrier (phase Ib)\n* Phase Ib only:\n\n  * More than 4 weeks since prior immunotherapy\n  * More than 4 weeks since prior biologic therapy\n  * No concurrent immunotherapy\n* Phase Ib and II:\n\n  * No concurrent prophylactic filgrastim (G-CSF)\n* Phase Ib only:\n\n  * More than 1 year since prior adjuvant docetaxel before metastatic relapse\n  * More than 4 weeks since prior chemotherapy and recovered\n  * No prior capecitabine AND docetaxel (in combination or as single agents)\n\n    * Prior capecitabine OR docetaxel allowed\n  * No other concurrent chemotherapy\n* Phase II only:\n\n  * No prior cytotoxic chemotherapy for breast cancer\n* Phase Ib only:\n\n  * More than 3 weeks since prior radiotherapy\n  * No prior radiotherapy to more than 25% of bone marrow\n  * No concurrent radiotherapy\n* Phase II only:\n\n  * No prior radiotherapy for breast cancer\n* Phase Ib only:\n\n  * More than 4 weeks since prior major surgery\n* Phase II only:\n\n  * No prior surgery (other than core or incisional biopsy for diagnostic purposes) for breast cancer\n* Phase Ib only:\n\n  * No other ancillary investigational therapy\n* Phase Ib and II:\n\n  * No concurrent sorivudine or brivudine",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}